Monoclonal Antibodies in Asthma: The choice between life and breath?

Table of Contents

• ABOUT DATAMONITOR HEALTHCARE
  • About the Infectious Diseases pharmaceutical analysis team
• CHAPTER 1 EXECUTIVE SUMMARY
  • Introduction
  • Scope and coverage of the Brief
  • Key findings from this Brief
• CHAPTER 2 DISEASE CLASSIFICATION AND EPIDEMIOLOGY
  • Asthma is a significant global health problem
  • Characterising asthma pathophysiology: the role of the Th2 pathway in asthma symptoms
    • The Th2 pathway plays a central role in asthma
    • A series of complex events underlie asthma symptoms
    • A broad range of mediators are involved in asthma pathophysiology
    • Asthma attacks are triggered by a wide variety of factors
  • Asthma is a collection of inflammatory respiratory conditions
    • Eosinophilic/mast cell asthma, and neutrophilic asthma
    • Atopic vs. non-atopic asthma and how it ties in with early-onset vs. late-onset asthma
    • Characterizing asthma by symptom frequency and severity
      • Characteristics of the severe asthma patient population
  • Corticosteroids and bronchodilators are currently the most common asthma treatments
• CHAPTER 3 USING MONOCLONAL ANTIBODIES TO TREAT ASTHMA
  • The evolution of the whole mAbs sector into a $10 billion market
    • Business model evolution
    • Therapy area evolution
  • Market potential for respiratory mAbs: the pros and cons with using mAbs for asthma
• CHAPTER 4 CURRENT RESPIRATORY MONOCLONAL ANTIBODY TREATMENTS FOR ASTHMA: XOLAIR
  • What is the rationale behind targeting IgE in asthma?
  • Xolair: a $1 billion market potential by 2015
  • Xolair's path to approval: what do other mAbs need to demonstrate?
  • Xolair label extension: opportunity in non-atopic asthma
• CHAPTER 5 PIPELINE INNOVATIONS AND POTENTIAL TARGETS
  • Targeting mediators that underlie asthma symptoms
    • The development of mAbs that target these mediators: the pipeline
    • Pipeline evaluation: IL-13 set to drive interest
  • Technology evolution: development of humanized and fully human mAbs set to drive market growth
  • Maximizing market potential by effective patient population capture: addressing clinical trial design issues
• APPENDIX
  • Bibliography
    • Papers
    • Miscellaneous
  • About Datamonitor
    • About Datamonitor Healthcare
    • Datamonitor Healthcare's research and analysis methodologies
  • Disclaimer
  • List of Tables
    • Table 1: Classification of asthma by symptom frequency and severity
    • Table 2: Xolair has demonstrated a range of effects in clinical trials
    • Table 3: Mediators thought to play a role in the aetiology of asthma
    • Table 4: Asthma mAbs currently in development
  • List of Figures
    • Figure 1: Key mediators and cells playing a role in the pathophysiology of asthma
    • Figure 2: Eosinophilic/mast cell and neutrophilic pathways
    • Figure 3: Characteristics of eosinophil positive and negative asthma
    • Figure 4: Percentage of asthma population with early or late-onset asthma
    • Figure 5: Severe persistent asthma makes up approximately one fifth of asthma incidence in Europe
    • Figure 6: Categorizing patients with severe asthma
    • Figure 7: Evolution of mAb developers towards fully-integrated status
    • Figure 8: Respiratory represents only a small percentage of mAb sales through to 2010
    • Figure 9: mAbs and anticholinergics power market growth
    • Figure 10: The pros and cons of using mAbs to treat asthma
    • Figure 11: 74,000 patients treated with Xolair by 2010, 74% in US market
    • Figure 12: Non-atopic is currently a significant untapped market for respiratory mAbs
    • Figure 13: Timeframe of asthma mAb development, based on mAb target